AVRO vs. FRLN, BDTX, IPSC, ADAP, CADL, MGX, IPHA, GNFT, ZURA, and IVVD
Should you be buying AVROBIO stock or one of its competitors? The main competitors of AVROBIO include Freeline Therapeutics (FRLN), Black Diamond Therapeutics (BDTX), Century Therapeutics (IPSC), Adaptimmune Therapeutics (ADAP), Candel Therapeutics (CADL), Metagenomi (MGX), Innate Pharma (IPHA), Genfit (GNFT), Zura Bio (ZURA), and Invivyd (IVVD). These companies are all part of the "medical" sector.
AVROBIO (NASDAQ:AVRO) and Freeline Therapeutics (NASDAQ:FRLN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.
AVROBIO's return on equity of -50.52% beat Freeline Therapeutics' return on equity.
62.6% of AVROBIO shares are owned by institutional investors. Comparatively, 46.3% of Freeline Therapeutics shares are owned by institutional investors. 9.2% of AVROBIO shares are owned by company insiders. Comparatively, 1.9% of Freeline Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
AVROBIO presently has a consensus target price of $2.00, suggesting a potential upside of 35.14%. Freeline Therapeutics has a consensus target price of $5.75, suggesting a potential downside of 11.27%. Given AVROBIO's higher probable upside, equities research analysts plainly believe AVROBIO is more favorable than Freeline Therapeutics.
AVROBIO received 138 more outperform votes than Freeline Therapeutics when rated by MarketBeat users. Likewise, 66.93% of users gave AVROBIO an outperform vote while only 64.15% of users gave Freeline Therapeutics an outperform vote.
In the previous week, AVROBIO had 2 more articles in the media than Freeline Therapeutics. MarketBeat recorded 2 mentions for AVROBIO and 0 mentions for Freeline Therapeutics. AVROBIO's average media sentiment score of 0.92 beat Freeline Therapeutics' score of 0.00 indicating that AVROBIO is being referred to more favorably in the media.
AVROBIO has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500. Comparatively, Freeline Therapeutics has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500.
Summary
AVROBIO beats Freeline Therapeutics on 11 of the 11 factors compared between the two stocks.
Get AVROBIO News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVRO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
